Postgraduate Institute of Medical Education and Research
Chandigarh, 160012, India
NCT Number: NCT04330508
Minimal hepatic encephalopathy (MHE) is an important clinical variant of hepatic encephalopathy (HE), which occurs in up to 60-70% of patients with cirrhosis. The condition comprises a cognitive impairment, observed in patients with cirrhosis who have no clinical evidence of overt hepatic encephalopathy (OHE). It is associated with an increased incidence of road traffic accidents, reduced quality of life and it affects the ability to perform tasks of daily living. Successful treatment of hepatitis C has been reported to be associated with 62-84% reduction in all-cause mortality (deaths), 68-79% reduction in risk of HCC and 90% reduction in risk of liver transplantation. In addition, studies have shown that viral eradication may improve cognition when given interferon based regimens for HCV. With the available of safe, efficacious, all oral regimens for HCV, we plan to prospectively analyse the change in mood, depression and cognitive function in response to DAA therapy, in relation to outcomes of treatment.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Observational
Chandigarh, 160012, India
Investigations will be performed according to the Declaration of Helsinki and approval of the enrolment as well as the usage of patient blood samples for research purpose will be obtained from the institutional ethics committee, and written informed consent will be obtained from all patients.The primary analysis upon which the sample size consideration was based involved the comparison of the SVR subgroup and the subgroup of patients without SVR. For the sample size calculation, we a two-factorial design (time course × SVR) with the use of a two-way analysis of variance (ANOVA) analysis, a significance level of 5% and a statistical power of at least 80% to detect a medium effect size (d = 0.5) and thus to show a significant group difference. Based on this background, the optimal sample size is calculated to be a total of 102 subjects. To consider asymmetric subgroups and to allow for a moderate dropout rate and additional calculations (secondary study objectives), we aim to include a total of at least 150 study participants in each group with 25 healthy volunteers as controls.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Health Related Quality of Life, neurocognitive tests, PHES
Other names: SF36
Time frame: Day 0
Computerized battery (Reaction times, simple and choice, visual memory, Number connection test, and Inhibitory Control Test)
Time frame: 90 days after treatment completion
Computerized battery (Reaction times, simple and choice, visual memory, Number connection test, and Inhibitory Control Test)
Time frame: Day 0
Psychometric hepatic encephalopathy score (PHES), Indian Version.
Time frame: 90 days after treatment completion
Psychometric hepatic encephalopathy score (PHES), Indian Version.
Time frame: Day 0
Time frame: 90 days after treatment completion
Time frame: Day 0
Beck's Depression Inventory (BDI) Generalized anxiety disorder (GAD 7 score) Psychometric hepatic encephalopathy Score (PHES) Montreal Cognitive assessment Score (MoCA Score)
Time frame: 90 days after treatment completion
Beck's Depression Inventory (BDI) Generalized anxiety disorder (GAD 7 score) Psychometric hepatic encephalopathy Score (PHES) Montreal Cognitive assessment Score (MoCA Score)
Post Graduate Institute of Medical Education and Research, Chandigarh
Other
Effects of Direct-acting Antiviral Agents on Cognitive Function, and Depression in Chronic Hepatitis C
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04943588
Blood-Borne Infections, Chronic Disease
Karachi, Pakistan
View Trial DetailsNCT05397067
Blood-Borne Infections, Chemically-Induced Disorders
Roanoke, Virginia, United States
View Trial DetailsNCT00148837
Blood-Borne Infections, Chronic Disease
Pessac, France
View Trial DetailsNCT01010646
Blood-Borne Infections, Chronic Disease
Lyon, France
View Trial Details